Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07364422 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 23, 2026 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer
Trial Details
NCT Number NCT07364422
Lead Sponsor Onconic Therapeutics Inc.
Conditions
(from sponsor)		 Gastric Cancer (GC)
Related terms Stomach Neoplasms
Enrollment 49 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov